These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 38132246)
1. Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders. Beyens M; Toscano A; Ebo D; Gülen T; Sabato V Diagnostics (Basel); 2023 Dec; 13(24):. PubMed ID: 38132246 [TBL] [Abstract][Full Text] [Related]
2. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. Valent P; Bonadonna P; Hartmann K; Broesby-Olsen S; Brockow K; Butterfield JH; Triggiani M; Lyons JJ; Oude Elberink JNG; Arock M; Metcalfe DD; Akin C Int Arch Allergy Immunol; 2019; 180(1):44-51. PubMed ID: 31256161 [TBL] [Abstract][Full Text] [Related]
3. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT. Valent P; Hoermann G; Bonadonna P; Hartmann K; Sperr WR; Broesby-Olsen S; Brockow K; Niedoszytko M; Hermine O; Chantran Y; Butterfield JH; Greiner G; Carter MC; Sabato V; Radia DH; Siebenhaar F; Triggiani M; Gülen T; Alvarez-Twose I; Staudinger T; Traby L; Sotlar K; Reiter A; Horny HP; Orfao A; Galli SJ; Schwartz LB; Lyons JJ; Gotlib J; Metcalfe DD; Arock M; Akin C J Allergy Clin Immunol Pract; 2023 Oct; 11(10):3010-3020. PubMed ID: 37572755 [TBL] [Abstract][Full Text] [Related]
4. Incorporating Tryptase Genotyping Into the Workup and Diagnosis of Mast Cell Diseases and Reactions. Lyons JJ; Greiner G; Hoermann G; Metcalfe DD J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1964-1973. PubMed ID: 35597543 [TBL] [Abstract][Full Text] [Related]
5. Mastocytosis and related entities: a practical roadmap. Beyens M; Elst J; van der Poorten ML; Van Gasse A; Toscano A; Verlinden A; Vermeulen K; Maes MB; Oude Elberink JNGH; Ebo D; Sabato V Acta Clin Belg; 2023 Aug; 78(4):325-335. PubMed ID: 36259506 [TBL] [Abstract][Full Text] [Related]
6. Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond. Sprinzl B; Greiner G; Uyanik G; Arock M; Haferlach T; Sperr WR; Valent P; Hoermann G Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671092 [TBL] [Abstract][Full Text] [Related]
7. Reversible Elevation of Tryptase Over the Individual's Baseline: Why is It the Best Biomarker for Severe Systemic Mast Cell Activation and MCAS? Valent P; Akin C; Arock M Curr Allergy Asthma Rep; 2024 Mar; 24(3):133-141. PubMed ID: 38308674 [TBL] [Abstract][Full Text] [Related]
8. The Curious Case of Elevated Tryptase: Workup and Differential in Family of Four. Cochran AL; Coop C; Neaves BI; Wood ST Cureus; 2023 Apr; 15(4):e38065. PubMed ID: 37228529 [TBL] [Abstract][Full Text] [Related]
9. Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology. Giannetti MP; Akin C; Hufdhi R; Hamilton MJ; Weller E; van Anrooij B; Lyons JJ; Hornick JL; Pinkus G; Castells M; Pozdnyakova O J Allergy Clin Immunol; 2021 Apr; 147(4):1497-1501.e1. PubMed ID: 33248113 [TBL] [Abstract][Full Text] [Related]
10. Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms. Chovanec J; Tunc I; Hughes J; Halstead J; Mateja A; Liu Y; O'Connell MP; Kim J; Park YH; Wang Q; Le Q; Pirooznia M; Trivedi NN; Bai Y; Yin Y; Hsu AP; McElwee J; Lassiter S; Nelson C; Bandoh J; DiMaggio T; Šelb J; Rijavec M; Carter MC; Komarow HD; Sabato V; Steinberg J; Hafer KM; Feuille E; Hourigan CS; Lack J; Khoury P; Maric I; Zanotti R; Bonadonna P; Schwartz LB; Milner JD; Glover SC; Ebo DG; Korošec P; Caughey GH; Brittain EH; Busby B; Metcalfe DD; Lyons JJ Blood Adv; 2023 May; 7(9):1796-1810. PubMed ID: 36170795 [TBL] [Abstract][Full Text] [Related]
11. Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Greiner G; Sprinzl B; Górska A; Ratzinger F; Gurbisz M; Witzeneder N; Schmetterer KG; Gisslinger B; Uyanik G; Hadzijusufovic E; Esterbauer H; Gleixner KV; Krauth MT; Pfeilstöcker M; Keil F; Gisslinger H; Nedoszytko B; Niedoszytko M; Sperr WR; Valent P; Hoermann G Blood; 2021 Jan; 137(2):238-247. PubMed ID: 32777817 [TBL] [Abstract][Full Text] [Related]
12. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium. Valent P; Hartmann K; Bonadonna P; Gülen T; Brockow K; Alvarez-Twose I; Hermine O; Niedoszytko M; Carter MC; Hoermann G; Butterfield JH; Lyons JJ; Sperr WR; Greiner G; Sotlar K; Kluin-Nelemans HC; Schwaab J; Lange M; George TI; Siebenhaar F; Broesby-Olsen S; Jawhar M; Nedoszytko B; Castells M; Orfao A; Gotlib J; Reiter A; Horny HP; Triggiani M; Arock M; Metcalfe DD; Akin C J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1941-1950. PubMed ID: 35623575 [TBL] [Abstract][Full Text] [Related]